Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

K-877-ER

Phase 2Small molecule

KKowa Research Institute, Inc.

K-877-ER is one of 50 small molecule programs targeting Fibrosis. It is currently in Phase 2.

2

Indications

3

Total Trials

0

Active Trials

49

Competitors

Pipeline

Status by Indication[3][1]

Indication

FibrosisActive, not recruiting

NASHCompleted

FibrosisPhase 2

Active, not recruiting

NASHPhase 2

Completed

Competition

Competitive Landscape

113 competitors in Fibrosis

#DrugCompanyPhaseTrials

Gleevec

PEG-Intron

Atacand

Esbriet

LLegacy Health System

Ofev

Boehringer Ingelheim

Ocaliva

IIntercept Pharmaceuticals

Myfortic

Nolvadex

Ozempic

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy1 trial

Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR

Completed·KKowa Research Institute, Inc.·Phase 2·NCT04447820·96 enrolled

Oral1 trial

Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452

Completed·KKowa Research Institute, Inc.·Phase 1·NCT05722262·30 enrolled

NASH1 trial

Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Participants With Noncirrhotic Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis

Completed·KKowa Research Institute, Inc.·Phase 2·NCT05327127·228 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for K-877-ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — K-877-ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for K-877-ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kowa Research Institute, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKowa Research Institute, Inc.

Related News